All Stories

  1. Patient research priority setting partnership in human T‐cell lymphotropic virus type I
  2. Worldwide Survey of Clinician Practice on use of Adjunctive Therapies Following Botulinum Toxin Injection for Spasticity
  3. “I wanna live and not think about the future” what place for advance care planning for people living with severe multiple sclerosis and their families? A qualitative study
  4. Prolonged disorders of consciousness: identification using the UK FIM + FAM and cohort analysis of outcomes from a UK national clinical database
  5. Do randomised controlled trials evaluating functional outcomes following botulinum neurotoxin-A align with focal spasticity guidelines? A systematic review
  6. The impact of spasticity and contractures on dependency and outcomes from rehabilitation
  7. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: A first psychometric evaluation
  8. The spasticity-related quality of life 6-dimensions instrument in upper-limb spasticity: Development and responsiveness
  9. A consensus process to agree best practice for managing physical wellbeing in people with a prolonged disorder of consciousness
  10. Stratified management of hemiplegic shoulder pain using an integrated care pathway: an 18-year clinical cohort analysis
  11. Investigating psychometric properties of the arm activity measure – Thai version (ArmA-TH) sub‐scales using the Rasch model
  12. Psychometric properties of measures of upper limb activity performance in adults with and without spasticity undergoing neurorehabilitation–A systematic review
  13. Longitudinal goal attainment with integrated upper limb spasticity management including repeat injections of botulinum toxin A: Findings from the prospective, observational Upper Limb International Spasticity (ULIS-III) cohort study
  14. Early Identification, Intervention and Management of Post-stroke Spasticity: Expert Consensus Recommendations
  15. Assessing the effectiveness of upper-limb spasticity management using a structured approach to goal-setting and outcome measurement: First cycle results from the ULIS-III Study
  16. A realist review of advance care planning for people with multiple sclerosis and their families
  17. Disability in Basic Activities of Daily Living Is Associated With Symptom Burden in Older People With Advanced Cancer or Chronic Obstructive Pulmonary Disease: A Secondary Data Analysis
  18. Trajectories of disability in activities of daily living in advanced cancer or respiratory disease: a systematic review
  19. A synthesis and appraisal of clinical practice guidelines, consensus statements and Cochrane systematic reviews for the management of focal spasticity in adults and children
  20. The Leg Activity measure, a new measure of passive and active function and impact on quality of life; informing goal setting and outcome evaluation in leg spasticity
  21. Goal-setting and attainment in prolonged disorders of consciousness – development of a structured approach
  22. Psychometric evaluation of the leg activity measure (LegA) for outcome measurement in people with brain injury and spasticity
  23. Preliminary evaluation of the reliability, validity and feasibility of the arm activity measure – Thai version (ArmA-TH) in cerebrovascular patients with upper limb hemiplegia
  24. Proceedings of SRR
  25. A comprehensive person-centered approach to adult spastic paresis: a consensus-based framework
  26. Spasticity management with botulinum toxin: A comparison of UK physiotherapy and rehabilitation medicine injectors
  27. Categorisation of goals set using Goal Attainment Scaling for treatment of leg spasticity: a multicentre analysis
  28. Rasch analysis of the UK Functional Assessment Measure in patients with complex disability after stroke
  29. Improving the management of post-stroke spasticity: Time for ACTION
  30. O-27 Rehabilitation provision across uk hospice services
  31. Time to retreatment with botulinum toxin A in upper limb spasticity management: Initial data from the Upper Limb International Spasticity (ULIS)-III study
  32. Poster 57: Time to Retreatment with Botulinum Toxin A in Upper Limb Spasticity Management: Initial Data from the Upper Limb International Spasticity (ULIS)-III Study
  33. Spasticity, what is the goal? Assessment, rehabilitation, and future perspectives
  34. Development of a measure of therapy provision for spasticity management in the paretic lower limb – the Leg Therapy recording Schedule (LegTS)
  35. Correlations between spasticity, goal attainment, and global assessment of benefits in patients with upper limb spasticity treated with botulinum toxin A
  36. Integrated upper limb spasticity management including botulinum toxin A (BoNT-A) on patient-centred goal attainment: Methodology for ULIS-III and initial goal-setting data
  37. A comparison of goal selection and achievement according to patient sex in the upper limb international spasticity (ULIS)-Ii study
  38. Relationship between abobotulinumtoxina injections into shoulder muscles and patient-centered primary goal selection and achievement: Subanalyses from the upper limb international spasticity (ULIS)-II study
  39. A comparison of goal selection and achievement between botulinum toxin A (BoNT-A) naïve and non-naïve patients in the upper limb international spasticity (ULIS)-II study
  40. Validity, reliability and ease of use of the disabilities of arm, shoulder and hand questionnaire in adults following stroke
  41. Poster 313 Relationship Between AbobotulinumtoxinA Injections into Shoulder Muscles and Patient Centred Primary Goal Selection and Achievement: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study
  42. Poster 373-C Integrated Upper Limb Spasticity Management Including Botulinum Toxin A (BoNT-A) on Patient-Centered Goal Attainment: Methodology for ULIS-III and Initial Goal-Setting Data
  43. Impact of integrated upper limb spasticity management including botulinum toxin A on patient-centred goal attainment: rationale and protocol for an international prospective, longitudinal cohort study (ULIS-III)
  44. Conceptualization and Development of the Leg Activity Measure (LegA) for Patient and Carer Reported Assessment of Activity in the Paretic Leg
  45. Common goal areas in the treatment of upper limb spasticity: a multicentre analysis
  46. A systematic review protocol to evaluate the psychometric properties of measures of function within adult neuro-rehabilitation
  47. Patient engagement and satisfaction with goal planning: Impact on outcome from rehabilitation
  48. Development of the leg activity measure (LEGA) for patient and care reported assessment of activity (function) in the paretic leg
  49. Rasch measurement: the Arm Activity measure (ArmA) passive function sub-scale
  50. Serial measurement of Wessex Head Injury Matrix in the diagnosis of patients in vegetative and minimally conscious states: a cohort analysis
  51. Factors Influencing Goal Attainment in Patients with Post-Stroke Upper Limb Spasticity Following Treatment with Botulinum Toxin A in Real-Life Clinical Practice: Sub-Analyses from the Upper Limb International Spasticity (ULIS)-II Study
  52. Goal setting, using goal attainment scaling, as a method to identify patient selected items for measuring arm function
  53. 110. Factors influencing goal attainment in patients with poststroke upper limb spasticity following treatment with botulinum neurotoxin A in real-life clinical practice: subanalyses from the Upper Limb International Spasticity (ULIS)-II Study
  54. Systematic review of patient-reported outcome measures for functional performance in the lower limb
  55. Supplementary prescribing for spasticity management
  56. Arm Activity measure (ArmA) application for recording functional gain following focal spasticity treatment
  57. Impact of soft-tissue-shortening on goal achievement in patients treated with botulinum-toxin a (BONT-A) for post-stroke upper-limb-spasticity (ULIS-2 study)
  58. Outcomes Related to Passive Function in a Cohort of Patients Treated With Botulinum Toxin A (Bont-A) for Post-Stroke Upper Limb Spasticity - ULIS II Study
  59. New guidelines on rehabilitation likely to restrict practices and stifle innovation
  60. The Ageing Body - Body Functions and Structures: Part 1
  61. Systematic Review of Upper-limb Function Measurement Methods in Botulinum Toxin Intervention for Focal Spasticity
  62. Initial psychometric evaluation of the Arm Activity Measure (ArmA): a measure of activity in the hemiparetic arm
  63. Conceptualisation and development of the arm activity measure (ArmA) for assessment of activity in the hemiparetic arm
  64. Poster 14: Physical Therapy and Botulinum Toxin-A (BoNT-A)—The Temporal Relationship Between Spasticity Reduction and Functional Gain
  65. Poster 435: A UK Pilot for a Large International Prospective Cohort Analysis of the Use of Botulinum Toxin A (BoNT-A) in Upper Limb Spasticity
  66. Poster 19: Psychometric Evaluation of the Arm Activity Measure (ArmA)—A Measure of Active and Passive Function in the Hemiparetic Arm
  67. Management of shoulder and proximal upper limb spasticity using botulinum toxin and concurrent therapy interventions: A preliminary analysis of goals and outcomes
  68. Evaluation of functional outcome measures for the hemiparetic upper limb: A systematic review
  69. Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb
  70. Goal attainment for spasticity management using botulinum toxin
  71. Why is the functional independence measure used to identify some rehabilitation needs in stroke survivors when there are better tools?
  72. Client Health Education and Empowerment through Physiotherapy in Neurorehabilitation
  73. Neurological Physiotherapy
  74. Serial Casting in New-born Infants for Correction of Soft Tissue Deformity Associated with Posterior Bowing of the Tibia
  75. Management of a patient diagnosed as PVS
  76. A comparison of the timing of muscle activity during sitting down compared to standing up